Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Mundipharma
Femme et Homme Max 99 ans
Mundipharma Research Ltd
MAJ Il y a 4 ans
A double-blind, randomised, incomplete block, crossover, placebo-controlled, dose-response study to assess bronchial hyperresponsiveness and airway inflammation effects of FlutiForm® pMDI low and high dose in adult subjects with mild to moderate asthma
The primary objective of this study is to demonstrate a dose-response relationship between high dose (250/10 µg, 2 puffs) and low dose (50/5 µg, 2 puffs) FlutiForm® by comparing the effects of each do...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Mundipharma Research Ltd
MAJ Il y a 4 ans
A double blind, double dummy, randomised, multicentre, four arm parallel group study to assess the efficacy and safety of FlutiForm™ pMDI 250/10 µg (2 puffs bid) vs Fluticasone pMDI 250 µg (2 puffs bid) plus Formoterol pMDI 12 µg (2 puffs bid) administered concurrently in adult subjects with severe persistent, reversible asthma
To show non-inferiority in the efficacy of FlutiForm pMDI 250/10 µg (2 puffs bid) vs Fluticasone pMDI 250 µg (2 puffs bid) plus Formoterol pMDI 12 µg (2 puffs bid) administered concurrently, based on ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Mundipharma Research GmbH & Co. KG
MAJ Il y a 4 ans
A study which assesses the effects of two pain medications: oxycodone/naloxone prolonged-release tablets (OXN PR) and oxycodone prolonged-release tablets (OxyPR) on the gastrointestinal system of subjects suffering from non-cancer pain
• Quantitative analysis of intestinal microbiota as determined in stool samples of subjects treated with OXN PR compared to those treated with OxyPR. • To assess orocaecal transit time on the basis o...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Mundipharma
MAJ Il y a 4 ans
Study of the efficacy of prolonged release oxycodone/naloxone (OXN PR), compared to prolonged release oxycodone (Oxy PR), for the reduction of the intensity of opioid-induced constipation symptoms in patients treated for cancer or non-cancer pain: A randomised, double-blind, controlled, multicentre study
The primary objective of this trial is to study the efficacy of oxycodone/naloxone prolonged release tablets (OXN PR), compared to oxycodone prolonged release tablets (Oxy PR), for the reduction of th...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Mundipharma Research Ltd
MAJ Il y a 4 ans
A double blind, double dummy, randomised, multicentre, two arm parallel group study to assess the efficacy and safety of FlutiForm® pMDI 125/5 µg (2 puffs bid) vs Symbicort® Turbohaler® 200/6 µg (2 puffs bid) in adolescent and adult subjects with moderate to severe persistent, reversible asthma
To show non-inferiority in the efficacy of FlutiForm® pMDI 125/5 µg (2 puffs bid) vs Symbicort® Turbohaler® 200/6 µg (2 puffs bid), based on the mean change in the pre-morning dose value of forced exp...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Mundipharma Research GmbH & Co. KG
MAJ Il y a 4 ans
A randomized, double-blind, parallel-group, multicenter study to demonstrate improvement in symptoms of constipation in subjects with non-malignant pain taking oxycodone equivalent of >= 20 mg/day and <= 50 mg/day as oxycodone / naloxone prolonged release compared to subjects taking oxycodone prolonged release tablets alone
The primary objective of this study is to demonstrate that subjects with moderate to severe non-malignant pain taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of const...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Mundipharma GmbH
MAJ Il y a 4 ans
An exploratory, randomised, parallel-group, open-label, multicentre study to assess the post-operative management of moderate to severe pain in patients who underwent laparoscopic cholecystectomy, receiving oxycodone hydrochloride i.v. within 12 - 24 hours after surgery at first and then oxycodone / naloxone prolonged release tablets compared to patients receiving piritramide infusions
The primary objectives of this trial is to demonstrate non-inferiority of oxycodone/naloxone prolonged release tablets (OXN) compared to piritramide infusions with respect to post operative pain inten...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Mundipharma Research Ltd (UK)
MAJ Il y a 4 ans
Phase III, open-label, randomised, multicentre efficacy and safety study of bendamustine hydrochloride versus chlorambucil in treatment-naive patients with (Binet Stage B/C) chronic B-Cell Lymphocytic Leukaemia (B-CLL) requiring therapy
Not provided at time of registration
Pays
Germany
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Mundipharma Comm VA
MAJ Il y a 4 ans
An open study with OXN to evaluate the patient preference for pain treatment with respect to quality of life after WHO step I or step II analgesics for patients with moderate to severe non-malignant pain
To determine the patient preference of OXN treatment compared to previous WHO step I or II analgesics with respect to quality of life (5 categories).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Mundipharma AB
MAJ Il y a 4 ans
A randomized, open, controlled parallel group, multi-center study to evaluate the efficacy and safety of Norspan versus Tiparol Retard in subjects with chronic, moderate to severe osteoarthritis pain of the hip and/or knee
To evaluate the efficacy and safety of norspan versus Tiparol Retard in subjects with chronic, moderate to severe osteoarthritis pain of the hip and/or knee.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
Suivant